S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
WARNING: Do You Invest with these Banks (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
WARNING: Do You Invest with these Banks (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
WARNING: Do You Invest with these Banks (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Tailor an Options Trading Strategy to Fit Your Needs (Ad)pixel
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
WARNING: Do You Invest with these Banks (Ad)pixel
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
US futures turn around on strong performance from retailers
WARNING: Do You Invest with these Banks (Ad)pixel
NASDAQ:OMCL

Omnicell - OMCL Stock Forecast, Price & News

$111.35
-0.88 (-0.78%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$109.11
$111.79
50-Day Range
$105.24
$124.09
52-Week Range
$103.62
$187.29
Volume
277,822 shs
Average Volume
499,687 shs
Market Capitalization
$4.93 billion
P/E Ratio
88.37
Dividend Yield
N/A
Price Target
$162.40

Omnicell MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
45.8% Upside
$162.40 Price Target
Short Interest
Bearish
7.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Omnicell in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$414,715 Sold Last Quarter
Proj. Earnings Growth
22.18%
From $2.75 to $3.36 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

357th out of 1,124 stocks

Electronic Computers Industry

5th out of 5 stocks

OMCL stock logo

About Omnicell (NASDAQ:OMCL) Stock

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

Wall Street Analyst Weigh In

Several research firms have commented on OMCL. SVB Leerink began coverage on shares of Omnicell in a report on Friday, July 15th. They issued a "market perform" rating and a $124.00 price objective on the stock. Piper Sandler cut their price objective on shares of Omnicell from $162.00 to $150.00 and set an "overweight" rating for the company in a research report on Monday, August 8th. TheStreet lowered Omnicell from a "b-" rating to a "c+" rating in a research note on Tuesday, May 17th. BTIG Research reduced their price target on Omnicell from $190.00 to $175.00 and set a "buy" rating for the company in a research note on Wednesday, July 27th. Finally, Wells Fargo & Company lowered their price objective on Omnicell from $188.00 to $158.00 and set an "overweight" rating on the stock in a research report on Tuesday, May 3rd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat.com, Omnicell currently has an average rating of "Moderate Buy" and an average target price of $162.40.

Omnicell Price Performance

NASDAQ:OMCL traded down $0.88 during trading hours on Tuesday, reaching $111.35. 277,822 shares of the company were exchanged, compared to its average volume of 499,687. The company has a market capitalization of $4.93 billion, a P/E ratio of 88.37, a P/E/G ratio of 3.64 and a beta of 1.05. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.11 and a quick ratio of 1.71. The business has a 50 day moving average of $112.51 and a 200 day moving average of $121.08. Omnicell has a 1-year low of $103.62 and a 1-year high of $187.29.

Omnicell (NASDAQ:OMCL - Get Rating) last released its earnings results on Thursday, August 4th. The company reported $0.84 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.01). The company had revenue of $331.39 million for the quarter, compared to analyst estimates of $339.45 million. Omnicell had a return on equity of 10.37% and a net margin of 4.82%. The business's revenue for the quarter was up 21.5% compared to the same quarter last year. During the same period last year, the company posted $0.71 earnings per share. Research analysts forecast that Omnicell will post 2.75 EPS for the current year.

Insider Activity at Omnicell

In other news, EVP Scott Peter Seidelmann sold 3,765 shares of Omnicell stock in a transaction on Thursday, June 16th. The stock was sold at an average price of $110.15, for a total value of $414,714.75. Following the transaction, the executive vice president now owns 40,789 shares in the company, valued at approximately $4,492,908.35. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 2.76% of the stock is currently owned by insiders.

Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Omnicell (NASDAQ:OMCL) PT Lowered to $150.00
Omnicell, Inc. (OMCL)
Omnicell: Q2 Earnings Snapshot
Omnicell Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electronic computers
Sub-Industry
Health Care Technology
Sector
Medical
Current Symbol
NASDAQ:OMCL
CUSIP
68213N10
Employees
3,800
Year Founded
1992

Price Target and Rating

Average Stock Price Forecast
$162.40
High Stock Price Forecast
$205.00
Low Stock Price Forecast
$124.00
Forecasted Upside/Downside
+45.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$77.85 million
Pretax Margin
3.65%

Debt

Sales & Book Value

Annual Sales
$1.13 billion
Cash Flow
$5.42 per share
Book Value
$26.09 per share

Miscellaneous

Free Float
43,067,000
Market Cap
$4.93 billion
Optionable
Optionable
Beta
1.05

Social Links















OMCL Stock - Frequently Asked Questions

Should I buy or sell Omnicell stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OMCL shares.
View OMCL analyst ratings
or view top-rated stocks.

What is Omnicell's stock price forecast for 2022?

5 analysts have issued 1 year price objectives for Omnicell's stock. Their OMCL share price forecasts range from $124.00 to $205.00. On average, they predict the company's stock price to reach $162.40 in the next year. This suggests a possible upside of 45.8% from the stock's current price.
View analysts price targets for OMCL
or view top-rated stocks among Wall Street analysts.

How have OMCL shares performed in 2022?

Omnicell's stock was trading at $180.44 at the beginning of the year. Since then, OMCL stock has decreased by 38.3% and is now trading at $111.35.
View the best growth stocks for 2022 here
.

When is Omnicell's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our OMCL earnings forecast
.

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) issued its earnings results on Thursday, August, 4th. The company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.85 by $0.01. The firm had revenue of $331.39 million for the quarter, compared to analysts' expectations of $339.45 million. Omnicell had a net margin of 4.82% and a trailing twelve-month return on equity of 10.37%. The firm's revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.71 earnings per share.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell issued an update on its FY 2022 earnings guidance on Thursday, August, 11th. The company provided EPS guidance of $3.85-$4.05 for the period, compared to the consensus earnings per share estimate of $3.94. The company issued revenue guidance of $1.39 billion-$1.41 billion, compared to the consensus revenue estimate of $1.40 billion.

What is Randall A. Lipps' approval rating as Omnicell's CEO?

150 employees have rated Omnicell Chief Executive Officer Randall A. Lipps on Glassdoor.com. Randall A. Lipps has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Adobe (ADBE), Micron Technology (MU), NVIDIA (NVDA), Applied Materials (AMAT), Alibaba Group (BABA) and Intel (INTC).

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Conestoga Capital Advisors LLC (3.80%), Macquarie Group Ltd. (2.75%), Clearbridge Investments LLC (2.60%), Lazard Asset Management LLC (2.00%), Geneva Capital Management LLC (1.90%) and Price T Rowe Associates Inc. MD (1.11%). Insiders that own company stock include Christine Marie Mellon, Dan S Johnston, James T Judson, Joanne B Bauer, Joseph Brian Spears, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann.
View institutional ownership trends
.

How do I buy shares of Omnicell?

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $111.35.

How much money does Omnicell make?

Omnicell (NASDAQ:OMCL) has a market capitalization of $4.93 billion and generates $1.13 billion in revenue each year. The company earns $77.85 million in net income (profit) each year or $1.26 on an earnings per share basis.

How many employees does Omnicell have?

The company employs 3,800 workers across the globe.

Does Omnicell have any subsidiaries?
The following companies are subsidiares of Omnicell: 340B Link Business, Aesynt, Aesynt B.V., Aesynt Holding B.V., Aesynt Holding Cooperatief U.A., Aesynt Pty Ltd., Aesynt S.r.l, Aruba S.r.l, Ateb Inc. , Health Robotics S.r.l., InPharmics, MTS Medication Technologies Inc., MTS Packing Systems Inc., Mach 4 Automatisierungs Technik GmbH, MedPak Holdings Inc., Omnicell (Beijing) Technology Co. Ltd., Omnicell GmbH, Omnicell International LLC, Omnicell Ltd., and Omnicell SAS.
Read More
When was Omnicell founded?

Omnicell was founded in 1992.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The official website for the company is www.omnicell.com. The company can be reached via phone at (650) 251-6100, via email at ir@omnicell.com, or via fax at 847-596-3402.

This page (NASDAQ:OMCL) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.